Delgocitinib
Delgocitinib is a topical Janus kinase (JAK) inhibitor approved for the treatment of atopic dermatitis (eczema). It works by inhibiting multiple JAK enzymes (JAK1, JAK2, JAK3, and TYK2) involved in inflammatory cytokine signaling, thereby reducing skin inflammation and associated symptoms such as itching, redness, and lesions. This medication is typically prescribed for adult patients with moderate to severe atopic dermatitis who have not responded adequately to conventional therapies.
A topical JAK inhibitor used to treat atopic dermatitis by blocking inflammatory signaling pathways in the skin.
Key facts at a glance
- ATC
- D11AH11
- RxNorm
- 2721163
- Generic
- Delgocitinib
- Class
- atc-d11
- Brands
- Anzupgo
- Availability
- rx
- Lactation
- unknown
- Routes
- topical
- Forms
- cream
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Delgocitinib is indicated for the treatment of atopic dermatitis (atopic eczema) in adults with moderate to severe disease when topical corticosteroids or calcineurin inhibitors are inadequate or inappropriate.
As a pan-JAK inhibitor, delgocitinib blocks the activity of JAK1, JAK2, JAK3, and TYK2 enzymes, preventing the activation of STAT signaling pathways that transmit inflammatory cytokine signals from cell surface receptors to the nucleus, thereby reducing inflammation and pruritus in affected skin.
Delgocitinib is for topical use only and should not be applied to infected skin, open wounds, or mucous membranes. Common adverse effects may include application site reactions. As a JAK inhibitor, there may be theoretical risks related to JAK class effects; patients should use this medication only as prescribed by their healthcare provider.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy